Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04073147
Other study ID # ML40029
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date May 12, 2020
Est. completion date November 25, 2021

Study information

Verified date January 2022
Source Klinikum Stuttgart
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.


Description:

This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma. Three dosing groups of venetoclax (600mg, 800mg, and 1000mg) are planned; dosing of obinutuzumab will be 1000mg for each dosing group. 15 patients are planned being included from two centers in Germany.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date November 25, 2021
Est. primary completion date November 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion criteria: 1. Age at inclusion = 18 to 80 years, in case of ECOG 0 to 1 age up to 85 years 2. Eastern Cooperative Group performance status (ECOG) = 3 3. Evaluable lymphoma manifestation in the CNS, either contrast-enhanced lesion in the brain parenchyma or measurable meningeal lesions. 4. Biopsy proven CD20 positive PCNSL at initial diagnosis or previous relapse/progression (re-biopsy at study inclusion is not mandatory for inclusion, but strongly recommended if time in remission is longer than 24 months). 5. At least one prior HD-MTX containing chemotherapy application (MTX dosed at = 1 g/m2 body surface area) before progression or relapse. 6. Confirmed relapsed or refractory PCNSL according to the IPCG response criteria with the following definition: Evidence of disease recurrence following PR/CR or uCR or no radiological response (SD or PD) as per the IPCG criteria to prior chemotherapy regimen(s), at least one of them containing high-dose methotrexate. 7. Absolute neutrophil count (ANC) of at least 1'500/µl 8. Platelet count of at least 50'000/µl 9. Adequate liver (alanine aminotransferase [ALAT] and AST = 3.0 x upper limit of normal [ULN] and total bilirubin = 1.5 x ULN) and kidney function (estimated = 30ml/min creatinine clearance according to Cockgroft-Gault formula) 10. Written informed consent 11. Recovery from toxicity from previous anti-lymphoma treatment to = grade 2 Exclusion criteria: 1. Known allergy to venetoclax or other components of the formulation 2. Known allergy to obinutuzumab or other components of the formulation 3. Primary ocular lymphomas without brain parenchymal involvement 4. Lymphoma relapse outside the CNS; extra CNS relapse needs to be ruled out by body CT scans (neck till pelvis) or PET-CT scans. 5. Contraindications for lumbar puncture at the discretion of the clinical investigator 6. Prior exposure to obinutuzumab or venetoclax 7. Other additional anti-lymphoma treatment, e.g. chemotherapy or radiotherapy 8. Active hepatitis B or C 9. HIV seropositivity 10. Chronic use of immunosuppressive drugs, e.g. steroids for systemic autoimmune disease 11. Active infections requiring treatment 12. Other active malignancies (except non-melanoma skin cancer). Prior malignancies without evidence of disease for at least 5 years are allowed 13. Patient is pregnant or breastfeeding, or expecting to conceive or father children within one year of finishing venetoclax and 18 months for obinutuzumab. 14. Prior allogeneic haematopoietic stem cell or solid organ transplantation 15. Therapeutic intervention in setting of other former interventional clinical trial within 30 days before the first IMP administration in VENOBI study; simultaneous participation in registry and diagnostic studies or follow up of an interventional trial is allowed 16. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial 17. Known or persistent abuse of medication, drugs or alcohol 18. Person who is in a relationship of dependence/employment with the sponsor or the investigator 19. Administration of moderate or strong CYP3A inhibitors or inducers within 1 week of initiation of venetoclax dosing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Venetoclax
Venetoclax per os
Obinutuzumab
ObintuzumabIV

Locations

Country Name City State
Germany Klinikum Stuttgart Stuttgart Baden-Württemberg

Sponsors (2)

Lead Sponsor Collaborator
Klinikum Stuttgart University Hospital Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics of venetoclax and obinutuzumab Serum concentration and CSF concentration (µg/ml) day 3, 15, and 28
Secondary Dose limiting toxicities Defined by CTCAE (version 5.0) Within the first 6 weeks
Secondary Best lymphoma response achieved during induction According to IPCG criteria During induction (3 months)
Secondary Progression-free survival 1 (PFS1) Time from the date of first dose until date of progression, relapse or death, whichever occurs first Up to 15 months
Secondary Overall survival Time from the date of first dose until date of death Up to 15 months
Secondary Progression-free survival 2 (PFS2) Time from the start of maintenance venetoclax treatment at week 12 until date of progression, relapse or death, whichever occurs first. Up to 12 months
Secondary Mutational landscape of lymphoma NGS test based on FoundationOne Heme® platform At baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05036564 - Diagnosis; Objective RespOnse; THErApy N/A
Recruiting NCT03569995 - [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04627753 - Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. Phase 2
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT05425654 - RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL Phase 2
Active, not recruiting NCT04443829 - Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma Phase 1
Recruiting NCT04006561 - Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Recruiting NCT04656431 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma Phase 1
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT02934204 - Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Phase 2
Recruiting NCT04947319 - Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Phase 2
Active, not recruiting NCT04134117 - Tisagenlecleucel In Primary CNS Lymphoma Phase 1
Withdrawn NCT03212807 - Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Phase 2